US · MDXG
MiMedx Group, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Marietta, GA 30062
- Website
- mimedx.com
Price · as of 2025-12-31
$3.68
Market cap 724.22M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $34.89 | +848.1% |
| Intrinsic Value(DCF) | $43.63 | +1,085.6% |
| Graham-Dodd Method(GD) | $3.25 | -11.74% |
| Graham Formula(GF) | $8.96 | +143.48% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $1.20 | $126.90 | $0.00 | $0.00 | $0.00 |
| 2012 | $5.50 | $53.58 | $0.00 | $0.00 | $0.00 |
| 2013 | $7.24 | $45.85 | $82,928.21 | $0.51 | $0.00 |
| 2014 | $9.84 | $850.18 | $42,847.51 | $1.10 | $6.09 |
| 2015 | $8.58 | $53.71 | $3,682.81 | $2.37 | $17.79 |
| 2016 | $8.69 | $47.55 | $329.82 | $1.63 | $4.25 |
| 2017 | $7.42 | $56.63 | $130.29 | $3.56 | $23.05 |
| 2018 | $3.09 | $33.29 | $21.06 | $0.00 | $0.00 |
| 2019 | $6.55 | $43.52 | $0.00 | $0.00 | $1.85 |
| 2020 | $9.16 | $31.38 | $0.00 | $0.00 | $3.70 |
| 2021 | $4.49 | $32.80 | $0.16 | $0.10 | $0.00 |
| 2022 | $3.85 | $29.92 | $0.00 | $0.00 | $0.00 |
| 2023 | $8.16 | $99.49 | $3.86 | $3.95 | $15.78 |
| 2024 | $7.89 | $31.91 | $13.58 | $2.62 | $4.72 |
| 2025 | $4.88 | $34.89 | $55.03 | $3.25 | $8.96 |
AI valuation
Our deep-learning model estimates MiMedx Group, Inc.'s (MDXG) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $34.89
- Current price
- $3.68
- AI upside
- +848.1%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$43.63
+1,085.6% upside
Graham-Dodd
$3.25
-11.74% upside
Graham Formula
$8.96
+143.48% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| MDXG | MiMedx Group, Inc. | $3.68 | 724.22M | +848% | +1,086% | -12% | +143% | 14.85 | 2.81 | 1.72 | 6.71 | 103.93 | 3.23 | 82.56% | 15.26% | 11.60% | 21.61% | 45.59% | 16.02% | 0.01 | 35.83 | 4.32 | 3.76 | -1.99 | 1429.00% | 1999.00% | 1311.00% | 10.12% | 1.15 | 71.03% | 0.00% | 0.00% | 12.22% | 8.71 | 7.63 | 1.33 | 7.43 |
| ATAI | Atai Beckley N.V | $3.63 | 684.71M | +564% | -83% | — | — | -1.61 | 2.08 | 785.20 | -1.41 | -0.59 | 2.15 | 100.00% | -33341.23% | -48463.96% | -83.53% | -126.85% | -66.27% | 0.21 | -32.87 | 3.21 | 2.55 | -0.05 | 27200.00% | -191.00% | -257.00% | -34.13% | -3.30 | -102.19% | 0.00% | 0.00% | 0.00% | -1.99 | -2.47 | 663.04 | -4.47 |
| CVAC | CureVac N.V. | $4.66 | 1.05B | +3,460% | -35% | +67% | +15,600% | 3.05 | 0.84 | 1.09 | 0.65 | — | 0.87 | 80.23% | 33.20% | 30.30% | 31.46% | 74.77% | 23.99% | 0.06 | — | 7.28 | 7.16 | -2.11 | -16102.00% | 89554.00% | -12582.00% | 14.31% | 1.41 | 41.31% | 0.00% | 0.00% | 14.10% | 0.77 | 1.64 | 0.25 | 2.92 |
| DNTH | Dianthus Therapeutics, In… | $55.19 | 2B | -29% | -75% | — | — | -9.42 | 2.27 | 128.39 | -5.19 | — | 2.27 | 100.00% | -1633.74% | -1362.77% | -32.60% | -273.59% | -30.71% | 0.00 | — | 15.22 | 14.96 | 0.21 | -6982.00% | 12063.00% | 11175.00% | -9.78% | -4.24 | -210.26% | 0.00% | 0.00% | 0.00% | -5.17 | -6.73 | 84.49 | 21.62 |
| INBX | Inhibrx Biosciences, Inc. | $74.13 | 1.08B | +370% | -93% | +699% | — | 0.12 | 1.47 | 982.91 | 0.03 | — | 1.47 | -1042.50% | -165724.00% | 843786.00% | 1905.92% | 1880.87% | 690.69% | 0.06 | -24.57 | 3.94 | 3.76 | -0.08 | -237695.00% | -8889.00% | -45.00% | -100.22% | -4.77 | 1117.95% | 0.00% | 0.00% | 39.05% | -0.16 | -0.26 | 260.17 | -3.58 |
| INVA | Innoviva, Inc. | $22.96 | 1.48B | +363% | -42% | +62% | +354% | 5.67 | 1.31 | 3.62 | 2.57 | 0.69 | 1.58 | 72.33% | 38.52% | 63.78% | 29.09% | 20.10% | 18.47% | 0.00 | 9.81 | 14.64 | 11.79 | -1.44 | 81667.00% | 1852.00% | 392.00% | 12.73% | 3.96 | 28.97% | 0.00% | 0.00% | 45.61% | 6.03 | 5.04 | 2.32 | 3.32 |
| NKTR | Nektar Therapeutics | $68.98 | 1.4B | -92% | -92% | — | — | -1.52 | 2.98 | 1.84 | -0.33 | — | 2.98 | 68.82% | -106.88% | -120.86% | -124.10% | 143.06% | -33.90% | 1.69 | -3.74 | 4.26 | 4.18 | -0.67 | -6017.00% | 922.00% | -842.00% | -97.90% | -2.86 | 241.42% | 0.00% | 0.00% | 15.02% | -0.27 | -0.16 | 0.29 | -16.15 |
| RAPP | Rapport Therapeutics, Inc… | $29.03 | 1.06B | — | — | — | — | -2.27 | 0.58 | — | 1.62 | -2.27 | 0.58 | 0.00% | — | — | -55.97% | 98.09% | -33.30% | 0.00 | — | 35.34 | 34.82 | 0.71 | 10000.00% | — | 13331.00% | -37.74% | -7.39 | 79.40% | 0.00% | 0.00% | 0.00% | 1.51 | 1.87 | — | 10.97 |
| SANA | Sana Biotechnology, Inc. | $4.21 | 1.12B | — | — | — | — | -2.23 | 2.38 | — | -2.10 | — | 11.75 | 0.00% | — | — | -99.17% | -144.07% | -50.03% | 0.38 | — | 3.54 | 3.36 | 0.13 | -2055.00% | — | -622.00% | -43.07% | -4.91 | -135.54% | 0.00% | 0.00% | 0.66% | -1.97 | -2.09 | — | -4.58 |
| SNDX | Syndax Pharmaceuticals, I… | $21.71 | 1.89B | +262% | +64,186% | — | — | -6.72 | 29.67 | 11.13 | -6.06 | — | 29.67 | 95.96% | -158.45% | -165.60% | -161.82% | 196.12% | -45.50% | 0.00 | -8.08 | 4.40 | 3.60 | 0.54 | -1153.00% | 62784.00% | 1756.00% | -16.85% | -2.69 | 232.09% | 0.00% | 0.00% | 17.03% | -5.58 | -4.71 | 8.84 | -1.10 |
| TSHA | Taysha Gene Therapies, In… | $4.53 | 1.24B | +543% | -85% | — | +183% | -4.90 | 6.12 | 52.53 | -4.11 | — | 6.12 | 100.00% | -1097.55% | -1071.62% | -121.94% | 1496.02% | -53.62% | 0.88 | -896.66 | 5.42 | 5.30 | 0.86 | -6284.00% | -4607.00% | 151.00% | -18.64% | -3.10 | 1334.73% | 0.00% | 0.00% | 0.00% | -3.96 | -4.43 | 43.43 | -3.26 |
About MiMedx Group, Inc.
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.
- CEO
- Joseph H. Capper
- Employees
- 837
- Beta
- 1.59
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($43.63 ÷ $3.68) − 1 = +1,085.6% (DCF, example).